Oliver Buck
Fondateur chez ITM Isotopen Technologien München AG
Profil
Oliver Buck is the founder of ITM Isotopen Technologien München AG, where he holds the title of Member-Supervisory Board starting in 2005.
Mr. Buck is also the founder of OncoBeta GmbH.
Currently, Mr. Buck is a Trustee at the International Centers for Precision Oncology Foundation and a Member-Supervisory Board at ITM Isotope Technologies Munich SE.
Previously, Mr. Buck held the position of Non-Independent Non-Executive Director at Telix Pharmaceuticals Ltd.
from 2017 to 2022.
Mr. Buck graduated from Technische Universität München.
Postes actifs de Oliver Buck
| Sociétés | Poste | Début |
|---|---|---|
ITM Isotopen Technologien München AG
 ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany. | Fondateur | 01/01/2005 |
ITM Isotope Technologies Munich SE
 ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011. | Directeur/Membre du Conseil | 01/01/2012 |
| International Centers for Precision Oncology Foundation | Directeur/Membre du Conseil | - |
Anciens postes connus de Oliver Buck
| Sociétés | Poste | Fin |
|---|---|---|
| TELIX PHARMACEUTICALS LIMITED | Directeur/Membre du Conseil | 18/05/2022 |
OncoBeta GmbH
 OncoBeta GmbH Medical SpecialtiesHealth Technology OncoBeta GmbH is a privately held medical device company based in Garching near Munich, Germany. The German company specializes in the development and commercialization of innovative therapies, particularly the epidermal radioisotope therapy Rhenium-SCT® for non-melanoma skin cancers and keloid scars. OncoBeta was founded in 2010 by Oliver Buck and Doris Zur Muehlen, and the CEO is Shannon D. Brown. | Fondateur | - |
Formation de Oliver Buck
| Technische Universität München | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TELIX PHARMACEUTICALS LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany. | Commercial Services |
OncoBeta GmbH
OncoBeta GmbH Medical SpecialtiesHealth Technology OncoBeta GmbH is a privately held medical device company based in Garching near Munich, Germany. The German company specializes in the development and commercialization of innovative therapies, particularly the epidermal radioisotope therapy Rhenium-SCT® for non-melanoma skin cancers and keloid scars. OncoBeta was founded in 2010 by Oliver Buck and Doris Zur Muehlen, and the CEO is Shannon D. Brown. | Health Technology |
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011. | Health Technology |
| International Centers for Precision Oncology Foundation |